Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,801 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cellular Therapy Clear all
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

NCT00460421
View directory record Official record
Conditions
Leukemia
Interventions
Palifermin, Total Body irradiation, Chemotherapy
Drug · Radiation
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
1 Year to 16 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

NCT00004006
View directory record Official record
Conditions
Retinoblastoma
Interventions
filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, autologous bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 15 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 10, 2026, 11:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Investigating How the Brain Processes Different Experiences

NCT06051084
View directory record Official record
Conditions
Anxiety
Interventions
App-Delivered Mindfulness Training (MT), App-Delivered Coloring
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 10, 2026, 11:15 AM EDT
Terminated Not applicable Interventional Results available

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

NCT03152526
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Interventions
Device
Lead sponsor
Miltenyi Biotec B.V. & Co. KG
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 10, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

NCT03493425
View directory record Official record
Conditions
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
154
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

NCT01556009
View directory record Official record
Conditions
Basal Cell Nevus Syndrome, Gorlin's Syndrome
Interventions
Vismodegib, Aminolevulinic acid %20 topical solution
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 10, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
View directory record Official record
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00841555
View directory record Official record
Conditions
Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions
temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

NCT01039155
View directory record Official record
Conditions
Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

SRS Study in Patients With Non-Small Cell Lung Cancer

NCT00489008
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 10, 2026, 11:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetrelimab, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Alamitos, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

NCT02234934
View directory record Official record
Conditions
Granulomatous Disease, Chronic, X-linked
Interventions
Lentiviral G1XCGD Gene Therapy
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
23 Months and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 10, 2026, 11:15 AM EDT
Recruiting No phase listed Observational

A Real-World Registry of Chronic Wounds and Ulcers

NCT02280733
View directory record Official record
Conditions
Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
Interventions
Usual care
Other
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 10, 2026, 11:15 AM EDT
Active, not recruiting No phase listed Observational

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Blood and tissue samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Results available

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

NCT01313936
View directory record Official record
Conditions
Neuroblastoma
Interventions
Metaiodobenzylguanidine (MIBG)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 10, 2026, 11:15 AM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Completed No phase listed Observational

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT05164016
View directory record Official record
Conditions
Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy, Hematologic Malignancy, Solid Organ Transplant, Hematopoietic Cell Transplant, Cellular Therapy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Neoadjuvant T-VEC in High Risk Early Melanoma

NCT04427306
View directory record Official record
Conditions
Melanoma
Interventions
T-Vec
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 10, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 10, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT05363111
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Actinium Ac 225-DOTA-Daratumumab, Daratumumab, Indium In 111-DOTA-Daratumumab
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 10, 2026, 11:15 AM EDT
Recruiting Not applicable Interventional

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

NCT04504604
View directory record Official record
Conditions
Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Interventions
FoundationOne CDx and FoundationOne Liquid CDx
Diagnostic Test
Lead sponsor
TargetCancer Foundation
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 10, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

NCT01720043
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 10, 2026, 11:15 AM EDT